These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 20611005)

  • 1. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
    Narciso-Schiavon JL; Freire FC; Suarez MM; Ferrari MV; Scanhola GQ; Schiavon Lde L; Carvalho Filho RJ; Ferraz ML; Silva AE
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):350-6. PubMed ID: 20611005
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antinuclear antibody positivity in patients with chronic hepatitis C: clinically relevant or an epiphenomenon?
    Narciso-Schiavon JL; Freire FC; Suarez MM; Ferrari MV; Scanhola GQ; Schiavon Lde L; de Carvalho Filho RJ; Ferraz ML; Silva AE
    Eur J Gastroenterol Hepatol; 2009 Apr; 21(4):440-6. PubMed ID: 19382301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinuclear antibody is associated with a more advanced fibrosis and lower RNA levels of hepatitis C virus in patients with chronic hepatitis C.
    Hsieh MY; Dai CY; Lee LP; Huang JF; Tsai WC; Hou NJ; Lin ZY; Chen SC; Wang LY; Chang WY; Chuang WL; Yu ML
    J Clin Pathol; 2008 Mar; 61(3):333-7. PubMed ID: 17545561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antinuclear antibodies (ANA) in chronic hepatitis C virus infection: correlates of positivity and clinical relevance.
    Yee LJ; Kelleher P; Goldin RD; Marshall S; Thomas HC; Alberti A; Chiaramonte M; Braconier JH; Hall AJ; Thursz MR
    J Viral Hepat; 2004 Sep; 11(5):459-64. PubMed ID: 15357653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the prevalence of autoantibodies in individuals with chronic hepatitis C and those with autoimmune hepatitis: the role of interferon in the development of autoimmune diseases.
    Bayraktar Y; Bayraktar M; Gurakar A; Hassanein TI; Van Thiel DH
    Hepatogastroenterology; 1997; 44(14):417-25. PubMed ID: 9164512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Serum autoantibodies of patients with chronic hepatitis C and the significance thereof in infection of hepatitis C virus].
    Wu CH; Xu XY; Tian GS; Yu YY
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(6):390-3. PubMed ID: 16677548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Detection and the production mechanism of antinuclear antibodies (ANA) and anti-liver/kidney microsomal tpe 1 antibodies (anti-LKM1) in patients with chronic hepatitis C].
    Bai L; Lu HY; Feng ZR; Yu M; Li WG; Gong WB; Zhao NE; Xu XY
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2009 Aug; 23(4):278-81. PubMed ID: 20108773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of antinuclear and anti-liver-kidney-microsome type-1 antibodies in patients with chronic hepatitis C in China.
    Bai L; Feng ZR; Lu HY; Li WG; Yu M; Xu XY
    Chin Med J (Engl); 2009 Jan; 122(1):5-9. PubMed ID: 19187609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response.
    Khairy M; El-Raziky M; El-Akel W; Abdelbary MS; Khatab H; El-Kholy B; Esmat G; Mabrouk M
    Liver Int; 2013 Nov; 33(10):1504-9. PubMed ID: 23763380
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of combination therapy with interferon-alpha and ribavirin for chronic hepatitis C in relation to liver fibrosis and serum aminotransferase activity].
    Karpińska E; Wawrzynowicz-Syczewska M; Jurczyk K; Morańska I; Urbanowicz W; Boroń-Kaczmarska A
    Wiad Lek; 2005; 58(11-12):616-21. PubMed ID: 16594470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C.
    Ferri S; Muratori L; Quarneti C; Muratori P; Menichella R; Pappas G; Granito A; Ballardini G; Bianchi FB; Lenzi M
    J Hepatol; 2009 Jun; 50(6):1093-101. PubMed ID: 19398235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile.
    Cassani F; Cataleta M; Valentini P; Muratori P; Giostra F; Francesconi R; Muratori L; Lenzi M; Bianchi G; Zauli D; Bianchi FB
    Hepatology; 1997 Sep; 26(3):561-6. PubMed ID: 9303483
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis.
    Roche B; Sebagh M; Canfora ML; Antonini T; Roque-Afonso AM; Delvart V; Saliba F; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2008 Dec; 14(12):1766-77. PubMed ID: 19025933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C.
    Abdelmalek MF; Firpi RJ; Soldevila-Pico C; Reed AI; Hemming AW; Liu C; Crawford JM; Davis GL; Nelson DR
    Liver Transpl; 2004 Feb; 10(2):199-207. PubMed ID: 14762857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for autoantibodies in chronic hepatitis C patients has no effect on treatment initiation or outcome.
    Mauss S; Berger F; Schober A; Moog G; Heyne R; John C; Pape S; Hueppe D; Pfeiffer-Vornkahl H; Alshuth U
    J Viral Hepat; 2013 Apr; 20(4):e72-7. PubMed ID: 23490392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineutrophil cytoplasmic antibody in patients with antinuclear antibody-positive chronic hepatitis C.
    Ohira H; Tojo J; Shinzawa J; Suzuki T; Miyata M; Nishimaki T; Kasukawa R
    Fukushima J Med Sci; 1998 Dec; 44(2):83-92. PubMed ID: 10091380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of specific antibodies to F protein in serum samples from Chinese hepatitis C patients treated with interferon plus ribavarin.
    Gao DY; Zhang XX; Hou G; Jin GD; Deng Q; Kong XF; Zhang DH; Ling Y; Yu DM; Gong QM; Zhan Q; Yao BL; Lu ZM
    J Clin Microbiol; 2008 Nov; 46(11):3746-51. PubMed ID: 18832124
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.